Polycythemia Vera Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$2000

Polycythemia Vera Pipeline Drugs Market Overview

Polycythemia Vera pipeline market research report provides comprehensive information on the therapeutics under development for Polycythemia Vera, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Polycythemia Vera and features dormant and discontinued projects.

Key Targets in the Polycythemia Vera Pipeline Market

The key targets in the Polycythemia Vera pipeline market are Tyrosine Protein Kinase JAK2, Interferon Alpha/Beta Receptor 1, Interferon Alpha/Beta Receptor 2, Bcl 2 Like Protein 1, Bcl 2 Like Protein 2, Hepcidin, and Histone Deacetylase 1. Tyrosine Protein Kinase JAK2 has the highest pipeline products.

Polycythemia Vera Pipeline Market, by Targets

Polycythemia Vera Pipeline Market, by Targets

For more target insights, download a free report sample

Key MoA in the Polycythemia Vera Pipeline Market

The types of key MoA in the Polycythemia Vera pipeline market are Tyrosine Protein Kinase JAK2 Inhibitor, Interferon Alpha/Beta Receptor 1 Agonist, Interferon Alpha/Beta Receptor 2 Agonist, Bcl 2 Like Protein 1 Inhibitor, Bcl 2 Like Protein 2 Inhibitor, Histone Deacetylase 1 Inhibitor, Histone Deacetylase 2 Inhibitor, and Transmembrane Protease Serine 6 Inhibitor. Tyrosine Protein Kinase JAK2 Inhibitor has the maximum number of pipeline products.

Polycythemia Vera Pipeline Market, by MoA

Polycythemia Vera Pipeline Market, by MoA

For more MoA insights, download a free report sample

Key RoA in the Polycythemia Vera Pipeline Market

The types of key RoA in the Polycythemia Vera pipeline market are subcutaneous, oral, intravenous, intramuscular, topical, intradermal, and intravenous drip. Subcutaneous has the majority number of pipeline products.

Polycythemia Vera Pipeline Market, by RoA

Polycythemia Vera Pipeline Market, by RoA

For more RoA insights, download a free report sample

Key Molecule Types in the Polycythemia Vera Pipeline Market

The key molecule types in the Polycythemia Vera pipeline market are small molecule, recombinant protein, subunit vaccine, peptide, antisense oligonucleotide, antisense RNAi oligonucleotide, monoclonal antibody, and synthetic peptide. Small molecule type has the highest number of pipeline products.

Polycythemia Vera Pipeline Market, by Molecule Types

Polycythemia Vera Pipeline Market, by Molecule Types

For more molecule type insights, download a free report sample

Key Companies in the Polycythemia Vera Pipeline Market

In the Polycythemia Vera pipeline market the key companies in are Protagonist Therapeutics Inc, Ascentage Pharma Group International, F. Hoffmann-La Roche Ltd, Fujifilm Holdings Corp, Hangzhou Bensheng Pharmaceutical Co Ltd, Imago BioSciences Inc, and Ionis Pharmaceuticals Inc. Protagonist Therapeutics Inc has the maximum number of pipeline products.

Polycythemia Vera Pipeline Market, by Companies

Polycythemia Vera Pipeline Market, by Companies

To know more about companies, download a free report sample

Market report overview

Key targets Tyrosine Protein Kinase JAK2, Interferon Alpha/Beta Receptor 1, Interferon Alpha/Beta Receptor 2, Bcl 2 Like Protein 1, Bcl 2 Like Protein 2, Hepcidin, and Histone Deacetylase 1
Key MoA Tyrosine Protein Kinase JAK2 Inhibitor, Interferon Alpha/Beta Receptor 1 Agonist, Interferon Alpha/Beta Receptor 2 Agonist, Bcl 2 Like Protein 1 Inhibitor Bcl 2 Like Protein 2 Inhibitor, Histone Deacetylase 1 Inhibitor, Histone Deacetylase 2 Inhibitor, and Transmembrane Protease Serine 6 Inhibitor
Key RoA Subcutaneous, Oral, Intravenous, Intramuscular, Topical, Intradermal, and Intravenous Drip
Key Molecule Types Small Molecule, Recombinant Protein, Subunit Vaccine, Peptide, Antisense Oligonucleotide, Antisense RNAi Oligonucleotide, Monoclonal Antibody, and Synthetic Peptide
Key Companies Protagonist Therapeutics Inc, Ascentage Pharma Group International, F. Hoffmann-La Roche Ltd, Fujifilm Holdings Corp, Hangzhou Bensheng Pharmaceutical Co Ltd, Imago BioSciences Inc, and Ionis Pharmaceuticals Inc

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Polycythemia Vera (Oncology)
  • The pipeline guide reviews pipeline therapeutics for Polycythemia Vera (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities
  • The pipeline guide reviews key companies involved in Polycythemia Vera (Oncology) therapeutics and enlists all their major and minor projects
  • The pipeline guide evaluates Polycythemia Vera (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects
  • The pipeline guide reviews latest news related to pipeline therapeutics for Polycythemia Vera (Oncology)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies
  • Recognize emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage
  • Find and recognize significant and varied types of therapeutics under development for Polycythemia Vera (Oncology)
  • Classify potential new clients or partners in the target demographic
  • Develop tactical initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics
  • Formulate corrective measures for pipeline projects by understanding Polycythemia Vera (Oncology) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline

AbbVie Inc
Ascentage Pharma Group International
F. Hoffmann-La Roche Ltd
Fujifilm Holdings Corp
Hangzhou Bensheng Pharmaceutical Co Ltd
Imago BioSciences Inc
Incyte Corp
IO Biotech Inc
Ionis Pharmaceuticals Inc
Italfarmaco SpA
Kartos Therapeutics Inc
Merganser Biotech Inc
PharmaEssentia Corp
Protagonist Therapeutics Inc
Shanghai Xunhe Pharmaceutical Technology Co Ltd
Silence Therapeutics Plc
Sino Biopharmaceutical Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Polycythemia Vera – Overview

Polycythemia Vera – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Polycythemia Vera – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Polycythemia Vera – Companies Involved in Therapeutics Development

Polycythemia Vera – Drug Profiles

Polycythemia Vera – Dormant Projects

Polycythemia Vera – Discontinued Products

Polycythemia Vera – Product Development Milestones

Featured News & Press Releases

Mar 02, 2022: NCCN clinical practice guidelines in oncology update recommends BESREMi (ropeginterferon alfa-2b-njft) for the treatment of polycythemia vera

Feb 15, 2022: German Federal Court of Justice upholds AOP’s license rights in ropeginterferon and PEC’s liability for damages

Dec 14, 2021: PharmaEssentia USA selects Veeva Data Cloud to support launch of novel therapy for rare, chronic blood cancer

Dec 12, 2021: Protagonist Therapeutics presents updated phase 2 rusfertide data in Polycythemia Vera (PV) at ASH 2021 Annual Meeting

Dec 06, 2021: BESREMi (ropeginterferon alfa-2b-njft), FDA approved for treatment of polycythemia vera, available at Biologics by McKesson

Nov 18, 2021: BESREMi (ropeginterferon alfa-2b-njft) now approved for the treatment of adults with polycythemia vera

Nov 15, 2021: BESREMi (Ropeginterferon alfa-2b) approved by the US FDA

Nov 12, 2021: U.S. FDA approves BESREMi (ropeginterferon alfa-2b-njft) as the only interferon for adults with polycythemia vera

Nov 04, 2021: Protagonist Therapeutics announces updated data from phase 2 study of Rusfertide in polycythemia vera selected for oral presentations at the ASH 2021 Annual Meeting

Oct 11, 2021: FDA lifts hold on Protagonist’s rusfertide clinical studies

Sep 20, 2021: FDA puts Protagonist Therapeutics’ rusfertide on clinical hold

Sep 14, 2021: PPMX-T003: Announcement on initiation of phase I clinical trial in polycythemia vera patients

Aug 10, 2021: Protagonist Therapeutics announces resolution of contract dispute with Zealand Pharma

Jun 11, 2021: Protagonist Therapeutics announces updated phase 2 data supporting long-term efficacy of Rusfertide in polycythemia vera

Jun 07, 2021: Protagonist Therapeutics to host Investor Conference Call and webcast to discuss updated Phase 2 Rusfertide results in Polycythemia Vera as presented at EHA 2021

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for Polycythemia Vera, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Polycythemia Vera – Pipeline by AbbVie Inc, 2022

Polycythemia Vera – Pipeline by Ascentage Pharma Group International, 2022

Polycythemia Vera – Pipeline by F. Hoffmann-La Roche Ltd, 2022

Polycythemia Vera – Pipeline by Fujifilm Holdings Corp, 2022

Polycythemia Vera – Pipeline by Hangzhou Bensheng Pharmaceutical Co Ltd, 2022

Polycythemia Vera – Pipeline by Imago BioSciences Inc, 2022

Polycythemia Vera – Pipeline by Incyte Corp, 2022

Polycythemia Vera – Pipeline by IO Biotech Inc, 2022

Polycythemia Vera – Pipeline by Ionis Pharmaceuticals Inc, 2022

Polycythemia Vera – Pipeline by Italfarmaco SpA, 2022

Polycythemia Vera – Pipeline by Kartos Therapeutics Inc, 2022

Polycythemia Vera – Pipeline by Merganser Biotech Inc, 2022

Polycythemia Vera – Pipeline by PharmaEssentia Corp, 2022

Polycythemia Vera – Pipeline by Protagonist Therapeutics Inc, 2022

Polycythemia Vera – Pipeline by Shanghai Xunhe Pharmaceutical Technology Co Ltd, 2022

Polycythemia Vera – Pipeline by Silence Therapeutics Plc, 2022

Polycythemia Vera – Pipeline by Sino Biopharmaceutical Ltd, 2022

Polycythemia Vera – Dormant Projects, 2022

Polycythemia Vera – Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development for Polycythemia Vera, 2022

Number of Products under Development by Companies, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage Molecule Types, 2022

Frequently asked questions

Polycythemia Vera Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$2,000

Can be used by individual purchaser only

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Polycythemia Vera Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Polycythemia Vera Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.